[ad_1]
LEPU ScienTech Medical Technology (Shanghai) (HKG:2291) Full Year 2022 Results
Key Financial Results
- Revenue: CN¥247.7m (up 11% from FY 2021).
- Net loss: CN¥19.8m (down by 134% from CN¥58.7m revenue in FY 2021).
- CN¥0.06 loss per share (down from CN¥0.19 revenue in FY 2021).
All figures proven within the chart above are for the trailing 12 month (TTM) interval
LEPU ScienTech Medical Technology (Shanghai)’s share worth is broadly unchanged from per week in the past.
Balance Sheet Analysis
While it is essential to think about the revenue and loss assertion, you can even study rather a lot about an organization by taking a look at its steadiness sheet. We have a graphic representation of LEPU ScienTech Medical Technology (Shanghai)’s balance sheet and an in-depth analysis of the company’s financial position.
Valuation is advanced, however we’re serving to make it easy.
Find out whether or not LEPU ScienTech Medical Technology (Shanghai) is probably over or undervalued by testing our complete evaluation, which incorporates honest worth estimates, dangers and warnings, dividends, insider transactions and monetary well being.
Have suggestions on this text? Concerned in regards to the content material? Get in touch with us immediately. Alternatively, e-mail editorial-team (at) simplywallst.com.
This article by Simply Wall St is basic in nature. We present commentary primarily based on historic knowledge and analyst forecasts solely utilizing an unbiased methodology and our articles aren’t supposed to be monetary recommendation. It doesn’t represent a suggestion to purchase or promote any inventory, and doesn’t take account of your goals, or your monetary state of affairs. We purpose to carry you long-term targeted evaluation pushed by basic knowledge. Note that our evaluation could not issue within the newest price-sensitive firm bulletins or qualitative materials. Simply Wall St has no place in any shares talked about.
[adinserter block=”4″]
[ad_2]
Source link